
Autoimmune Encephalitis and Paraneoplastic Syndrome
Current Knowledge and Updates
- 1st Edition - March 1, 2026
- Editor: Shitiz Sriwastava
- Language: English
- Paperback ISBN:9 7 8 - 0 - 4 4 3 - 3 3 1 0 8 - 4
- eBook ISBN:9 7 8 - 0 - 4 4 3 - 3 3 1 0 9 - 1
Autoimmune Encephalitis and Paraneoplastic Syndrome: Current Knowledge and Updates provides an overview of the immune-driven disorders of the nervous system, particularly autoim… Read more
Purchase options

- Offers a thorough reference for autoimmune encephalitis and paraneoplastic syndrome, including defining and classifying disorders and examining recent treatment guidelines
- Incorporates tools like flow charts, decision trees, and clinical examples to aid comprehension and application in real-world clinical settings
- Highlights ongoing research limitations while emphasizing the importance of recent advancements
- Provides specific guidance on newer antibodies including KLHL11 and LUZP4
2. General approach to diagnosis and work up for autoimmune encephalitis
3. Pathogenesis, pathophysiology and disease mechanism of neuronal antibody mediated encephalitis
4. Classification of Autoimmune Encephalitis
5. Recent Treatment Guidelines and approach toward autoimmune encephalitis
6. Newer autoimmune syndromes and updates on clinical trials
7. Neuroimaging and biomarkers in autoimmune CNS disorders
- Edition: 1
- Published: March 1, 2026
- Language: English
SS
Shitiz Sriwastava
Dr. Shitiz K. Sriwastava, MD, is an Assistant Professor in the Department of Neurology with the Division of Multiple Sclerosis and Neuroimmunology at the University of Texas Health Science Center – Houston (UTHealth). He is a board-certified neurologist specialized in multiple sclerosis (MS). During his fellowship training and residency at Wayne State, he performed clinical research on MS and related autoimmune disorders of the central nervous system. He has had many years of experience in MS related clinical trials as a fellow or co-investigator. Dr. Sriwastava has a keen interest in identifying prognostic markers to predict the initiation and progression of MS especially early neurogenerative changes and also DTI studies in MS. He is currently a member of the American Academy of Neurology. His clinical, basic and translational studies in neuroimmunologic diseases have resulted in 50 peer reviewed papers and reports, published abstracts from national and international meetings.